To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of HRS-9231 injection in a single dose in healthy subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Enrollment
40
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Adverse events, serious adverse events
Time frame: From ICF signing date to Day10
Cmax:maximum concentration measured. Blood samples were taken to assess HRS-9231 concentration
Time frame: From baseline (1 hour before injection) to 12 hours post-injection
t1/2 = terminal elimination half-life of the compound
Time frame: From baseline (1 hour before injection) to 12 hours post-injection
Cl = total clearance
Time frame: From baseline (1 hour before injection) to 12 hours post-injection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.